To provide a vaccine, preferably for human use, for symptom relaxant or prevention of evoked IgE-mediated allergic reactions.

This vaccine contains a protein having the entire amino acid sequence of constant CH2-CH3 domains in the epsilon chain of an IgE molecule or a structurally stable unit of the amino acid sequence, the protein optionally being coupled to one or more heterologous carrier proteins, and optionally containing an adjuvant. The vaccine is injected, with or without adjuvant, to raise the concentration of endogenous anti-IgE antibodies in the plasma of allergy subjects. In practice, the vaccine can be used against all types of IgE-mediated allergies since the antibodies are not dependent on the antigen specificity of the IgE molecule but can reduce the total IgE pool of the subject. Therefore, the vaccine is aimed at being used for treatment of subjects having different types of IgE-mediated allergies.